Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Skeletal Radiology

16-03-2024 | Positron Emission Tomography | Review Article

Multimodal positron emission tomography (PET) imaging in non-oncologic musculoskeletal radiology

Authors: Feliks Kogan, Daehyun Yoon, Matthew G. Teeter, Abhijit J. Chaudhari, Laurel Hales, Marco Barbieri, Garry E. Gold, Yael Vainberg, Ananya Goyal, Lauren Watkins

Published in: Skeletal Radiology

Login to get access

Abstract

Musculoskeletal (MSK) disorders are associated with large impacts on patient’s pain and quality of life. Conventional morphological imaging of tissue structure is limited in its ability to detect pain generators, early MSK disease, and rapidly assess treatment efficacy. Positron emission tomography (PET), which offers unique capabilities to evaluate molecular and metabolic processes, can provide novel information about early pathophysiologic changes that occur before structural or even microstructural changes can be detected. This sensitivity not only makes it a powerful tool for detection and characterization of disease, but also a tool able to rapidly assess the efficacy of therapies. These benefits have garnered more attention to PET imaging of MSK disorders in recent years. In this narrative review, we discuss several applications of multimodal PET imaging in non-oncologic MSK diseases including arthritis, osteoporosis, and sources of pain and inflammation. We also describe technical considerations and recent advancements in technology and radiotracers as well as areas of emerging interest for future applications of multimodal PET imaging of MSK conditions. Overall, we present evidence that the incorporation of PET through multimodal imaging offers an exciting addition to the field of MSK radiology and will likely prove valuable in the transition to an era of precision medicine.
Literature
1.
Kasaeian A, Roemer FW, Ghotbi E, Ibad HA, He J, Wan M, et al. Subchondral bone in knee osteoarthritis: bystander or treatment target? Skeletal Radiol. 2023;52(11):2069–83.PubMedCrossRef
2.
Watkins L, MacKay J, Haddock B, Mazzoli V, Uhlrich S, Gold G, et al. Assessment of quantitative [(18)F]sodium fluoride PET measures of knee subchondral bone perfusion and mineralization in osteoarthritic and healthy subjects. Osteoarthr Cartil. 2021;29(6):849–58.CrossRef
3.
Kogan F, Fan AP, McWalter EJ, Oei EHG, Quon A, Gold GE. PET/MRI of metabolic activity in osteoarthritis: a feasibility study. J Magn Reson Imaging. 2017;45(6):1736–45.PubMedCrossRef
4.
Kobayashi N, Inaba Y, Tateishi U, Yukizawa Y, Ike H, Inoue T, et al. New application of 18F-fluoride PET for the detection of bone remodeling in early-stage osteoarthritis of the hip. Clin Nucl Med. 2013;38(10):e379–83.PubMedCrossRef
5.
Kobayashi N, Inaba Y, Tateishi U, Ike H, Kubota S, Inoue T, et al. Comparison of 18F-fluoride positron emission tomography and magnetic resonance imaging in evaluating early-stage osteoarthritis of the hip. Nucl Med Commun. 2015;36(1):84–9.PubMedCrossRef
6.
MacKay JW, Watkins L, Gold G, Kogan F. [(18)F]NaF PET-MRI provides direct in-vivo evidence of the association between bone metabolic activity and adjacent synovitis in knee osteoarthritis: a cross-sectional study. Osteoarthr Cartil. 2021;29(8):1155–62.CrossRef
7.
Kogan F, Fan AP, Monu UD, Iagaru A, Hargreaves BA, Gold GE. Quantitative imaging of bone-cartilage interactions in ACL-injured patients with PET-MRI. Osteoarthr Cartil. 2018;26(6):790–6.CrossRef
8.
Savic D, Pedoia V, Seo Y, Yang J, Bucknor M, Franc BL, et al. Imaging bone-cartilage interactions in osteoarthritis using [18F]-NaF PET-MRI. Mol Imaging. 2016;15:1–12.PubMedCrossRef
9.
Tibrewala R, Pedoia V, Bucknor M, Majumdar S. Principal component analysis of simultaneous PET-MRI reveals patterns of bone-cartilage interactions in osteoarthritis. J Magn Reson Imaging. 2020;52(5):1462–74.PubMedCrossRef
10.
Tibrewala R, Bahroos E, Mehrabian H, Foreman SC, Link TM, Pedoia V, et al. [(18) F]-Sodium fluoride PET/MR imaging for bone-cartilage interactions in hip osteoarthritis: a feasibility study. J Orthop Res. 2019;37(12):2671–80.PubMedPubMedCentralCrossRef
11.
Parsons MA, Moghbel M, Saboury B, Torigian DA, Werner TJ, Rubello D, et al. Increased 18F-FDG uptake suggests synovial inflammatory reaction with osteoarthritis: preliminary in-vivo results in humans. Nucl Med Commun. 2015;36(12):1215–9.PubMedPubMedCentralCrossRef
12.
Nguyen BJ, Burt A, Baldassarre RL, Smitaman E, Morshedi M, Kao S, et al. The prognostic and diagnostic value of 18F-FDG PET/CT for assessment of symptomatic osteoarthritis. Nucl Med Commun. 2018;39(7):699–706.PubMedPubMedCentralCrossRef
13.
Haddock B, Fan AP, Uhlrich SD, Jorgensen NR, Suetta C, Gold GE, et al. Assessment of acute bone loading in humans using [(18)F]NaF PET/MRI. Eur J Nucl Med Mol Imaging. 2019;46(12):2452–63.PubMedPubMedCentralCrossRef
14.
Watkins LE, Haddock B, MacKay JW, Baker J, Uhlrich SD, Mazzoli V, et al. [(18)F]Sodium fluoride PET-MRI detects increased metabolic bone response to whole-joint loading stress in osteoarthritic knees. Osteoarthr Cartil. 2022;30(11):1515–25.CrossRef
15.
Beckers C, Ribbens C, Andre B, Marcelis S, Kaye O, Mathy L, et al. Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J Nucl Med. 2004;45(6):956–64.PubMed
16.
Roivainen A, Hautaniemi S, Mottonen T, Nuutila P, Oikonen V, Parkkola R, et al. Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs. Eur J Nucl Med Mol Imaging. 2013;40(3):403–10.PubMedCrossRef
17.
Hamar A, Hascsi Z, Pusztai A, Czokolyova M, Vegh E, Petho Z, et al. Prospective, simultaneous assessment of joint and vascular inflammation by PET/CT in tofacitinib-treated patients with rheumatoid arthritis: associations with vascular and bone status. RMD Open. 2021;7(3):e001804.
18.
Kubota K, Yamashita H, Mimori A. Clinical value of FDG-PET/CT for the evaluation of rheumatic diseases: rheumatoid arthritis, polymyalgia rheumatica, and relapsing polychondritis. Semin Nucl Med. 2017;47(4):408–24.PubMedCrossRef
19.
Hotta M, Minamimoto R, Kaneko H, Yamashita H. Fluorodeoxyglucose PET/CT of arthritis in rheumatic diseases: a pictorial review. Radiographics. 2020;40(1):223–40.PubMedCrossRef
20.
Chaudhari AJ, Ferrero A, Godinez F, Yang K, Shelton DK, Hunter JC, et al. High-resolution (18)F-FDG PET/CT for assessing disease activity in rheumatoid and psoriatic arthritis: findings of a prospective pilot study. Br J Radiol. 2016;89(1063):20160138.PubMedPubMedCentralCrossRef
21.
Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013;54(4):647–58.PubMedCrossRef
22.
van der Bruggen W, Bleeker-Rovers CP, Boerman OC, Gotthardt M, Oyen WJ. PET and SPECT in osteomyelitis and prosthetic bone and joint infections: a systematic review. Semin Nucl Med. 2010;40(1):3–15.PubMedCrossRef
23.
Pijl JP, Nienhuis PH, Kwee TC, Glaudemans A, Slart R, Gormsen LC. Limitations and pitfalls of FDG-PET/CT in infection and inflammation. Semin Nucl Med. 2021;51(6):633–45.PubMedCrossRef
24.
van der Krogt JMA, van Binsbergen WH, van der Laken CJ, Tas SW. Novel positron emission tomography tracers for imaging of rheumatoid arthritis. Autoimmun Rev. 2021;20(3):102764.PubMedCrossRef
25.
van der Laken CJ, Elzinga EH, Kropholler MA, Molthoff CF, van der Heijden JW, Maruyama K, et al. Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography. Arthritis Rheum. 2008;58(11):3350–5.PubMedCrossRef
26.
Bruijnen S, Tsang ASM, Raterman H, Ramwadhdoebe T, Vugts D, van Dongen G, et al. B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients. Arthritis Res Ther. 2016;18(1):266.PubMedPubMedCentralCrossRef
27.
Zhu Z, Yin Y, Zheng K, Li F, Chen X, Zhang F, et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using (6)(8)Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study. Ann Rheum Dis. 2014;73(6):1269–72.PubMedCrossRef
28.
Reilly CC, Raynor WY, Hong AL, Kargilis DC, Lee JS, Alecxih AG, et al. Diagnosis and monitoring of osteoporosis with (18)F-sodium fluoride PET: an unavoidable path for the foreseeable future. Semin Nucl Med. 2018;48(6):535–40.PubMedCrossRef
29.
Frost ML, Fogelman I, Blake GM, Marsden PK, Cook G Jr. Dissociation between global markers of bone formation and direct measurement of spinal bone formation in osteoporosis. J Bone Miner Res. 2004;19(11):1797–804.PubMedCrossRef
30.
Uchida K, Nakajima H, Miyazaki T, Yayama T, Kawahara H, Kobayashi S, et al. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study. J Nucl Med. 2009;50(11):1808–14.PubMedCrossRef
31.
Park PSU, Resto DA, Khurana N, Raynor WY, Werner TJ, Hoilund-Carlsen PF, et al. The utility of 18 F-NaF-positron emission tomography/computed tomography in measuring the metabolic activity of the aging spine : implications for osteoporosis. Spine (Phila Pa 1976). 2023;48(15):1064–71.PubMedCrossRef
32.
Eastell R, O’Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, et al. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2:16069.PubMedCrossRef
33.
34.
Sheppard AJ, Paravastu SS, Wojnowski NM, Osamor CC 3rd, Farhadi F, Collins MT, et al. Emerging role of (18)F-NaF PET/computed tomographic imaging in osteoporosis: a potential upgrade to the osteoporosis toolbox. PET Clin. 2023;18(1):1–20.PubMedPubMedCentralCrossRef
35.
Frost ML, Siddique M, Blake GM, Moore AE, Schleyer PJ, Dunn JT, et al. Differential effects of teriparatide on regional bone formation using (18)F-fluoride positron emission tomography. J Bone Miner Res. 2011;26(5):1002–11.PubMedCrossRef
36.
Frost ML, Siddique M, Blake GM, Moore AE, Marsden PK, Schleyer PJ, et al. Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women. Osteoporos Int. 2012;23(8):2107–16.PubMedCrossRef
37.
Frost ML, Cook GJ, Blake GM, Marsden PK, Benatar NA, Fogelman I. A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18F-fluoride positron emission tomography. J Bone Miner Res. 2003;18(12):2215–22.PubMedCrossRef
38.
Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49(1):68–78.PubMedCrossRef
39.
Staats PS, Silverman SM. Controlled substance management in chronic pain: a balanced approach, 1st edn. Cham: Springer; 2016.
40.
St Sauver JL, Warner DO, Yawn BP, Jacobson DJ, McGree ME, Pankratz JJ, et al. Why patients visit their doctors: assessing the most prevalent conditions in a defined American population. Mayo Clin Proc. 2013;88(1):56–67.PubMedCrossRef
41.
Horga LM, Hirschmann AC, Henckel J, Fotiadou A, Di Laura A, Torlasco C, et al. Prevalence of abnormal findings in 230 knees of asymptomatic adults using 3.0 T MRI. Skeletal Radiol. 2020;49(7):1099–107.PubMedPubMedCentralCrossRef
42.
Gill TK, Shanahan EM, Allison D, Alcorn D, Hill CL. Prevalence of abnormalities on shoulder MRI in symptomatic and asymptomatic older adults. Int J Rheum Dis. 2014;17(8):863–71.PubMedCrossRef
43.
Brinjikji W, Luetmer PH, Comstock B, Bresnahan BW, Chen LE, Deyo RA, et al. Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. AJNR Am J Neuroradiol. 2015;36(4):811–6.PubMedPubMedCentralCrossRef
44.
Takatalo J, Karppinen J, Niinimaki J, Taimela S, Mutanen P, Sequeiros RB, et al. Association of modic changes, Schmorl’s nodes, spondylolytic defects, high-intensity zone lesions, disc herniations, and radial tears with low back symptom severity among young Finnish adults. Spine (Phila Pa 1976). 2012;37(14):1231–9.PubMedCrossRef
45.
Cipriano PW, Yoon D, Gandhi H, Holley D, Thakur D, Hargreaves BA, et al. (18)F-FDG PET/MRI in chronic sciatica: early results revealing spinal and nonspinal abnormalities. J Nucl Med. 2018;59(6):967–72.PubMedCrossRef
46.
Cipriano PW, Yoon D, Holley D, Hargreaves BA, Carroll IR, Curtin CM, et al. Diagnosis and successful management of an unusual presentation of chronic foot pain using positron emission tomography/magnetic resonance imaging and a simple surgical procedure. Clin J Sport Med. 2020;30(1):e11–4.PubMedPubMedCentralCrossRef
47.
Yoon D, Xu Y, Cipriano PW, Alam IS, Mari Aparici C, Tawfik VL, et al. Neurovascular, muscle, and skin changes on [18F]FDG PET/MRI in complex regional pain syndrome of the foot: a prospective clinical study. Pain Med. 2022;23(2):339–46.PubMedCrossRef
48.
Gaber T, Strehl C, Buttgereit F. Metabolic regulation of inflammation. Nat Rev Rheumatol. 2017;13(5):267–79.PubMedCrossRef
49.
Draper CE, Fredericson M, Gold GE, Besier TF, Delp SL, Beaupre GS, et al. Patients with patellofemoral pain exhibit elevated bone metabolic activity at the patellofemoral joint. J Orthop Res. 2012;30(2):209–13.PubMedCrossRef
50.
Jenkins NW, Talbott JF, Shah V, Pandit P, Seo Y, Dillon WP, et al. [(18)F]-Sodium fluoride PET MR-based localization and quantification of bone turnover as a biomarker for facet joint-induced disability. AJNR Am J Neuroradiol. 2017;38(10):2028–31.PubMedPubMedCentralCrossRef
51.
Mabray MC, Brus-Ramer M, Behr SC, Pampaloni MH, Majumdar S, Dillon WP, et al. (18)F-Sodium fluoride PET-CT hybrid imaging of the lumbar facet joints: tracer uptake and degree of correlation to CT-graded arthropathy. World J Nucl Med. 2016;15(2):85–90.PubMedPubMedCentralCrossRef
52.
Spirig JM, Hullner M, Cornaz F, Betz M, Wanivenhaus F, Hofbauer M, et al. [18F]-Sodium fluoride PET/MR for painful lumbar facet joint degeneration - a randomized controlled clinical trial. Spine J. 2022;22(5):769–75.PubMedCrossRef
53.
Hjornevik T, Cipriano PW, Shen B, Park JH, Gulaka P, Holley D, et al. Biodistribution and radiation dosimetry of (18)F-FTC-146 in humans. J Nucl Med. 2017;58(12):2004–9.PubMedPubMedCentralCrossRef
54.
Zamanillo D, Romero L, Merlos M, Vela JM. Sigma 1 receptor: a new therapeutic target for pain. Eur J Pharmacol. 2013;716(1–3):78–93.PubMedCrossRef
55.
Jercic L, Kostic S, VitlovUljevic M, VukusicPusic T, Vukojevic K, Filipovic N. Sigma-1 receptor expression in DRG neurons during a carrageenan-provoked inflammation. Anat Rec (Hoboken). 2019;302(9):1620–7.PubMedCrossRef
56.
Kwon SG, Roh DH, Yoon SY, Choi SR, Choi HS, Moon JY, et al. Role of peripheral sigma-1 receptors in ischaemic pain: potential interactions with ASIC and P2X receptors. Eur J Pain. 2016;20(4):594–606.PubMedCrossRef
57.
Cipriano PW, Lee SW, Yoon D, Shen B, Tawfik VL, Curtin CM, et al. Successful treatment of chronic knee pain following localization by a sigma-1 receptor radioligand and PET/MRI: a case report. J Pain Res. 2018;11:2353–7.PubMedPubMedCentralCrossRef
58.
Yoon D, Cipriano P, Biswal S. Sigma-1 receptor PET-MRI for imaging nociceptive sources of low back pain. Proc Intl Soc Mag Res Med. 2020;3060.
59.
Dubin JA, Bains SS, Paulson AE, Monarrez R, Hameed D, Nace J, et al. The current epidemiology of revision total knee arthroplasty in the United States from 2016 to 2022. J Arthroplasty. 2023;39(3):760–5.PubMedCrossRef
60.
Kandahari AM, Yang X, Laroche KA, Dighe AS, Pan D, Cui Q. A review of UHMWPE wear-induced osteolysis: the role for early detection of the immune response. Bone Res. 2016;4:16014.PubMedPubMedCentralCrossRef
61.
Expert Panel on Musculoskeletal I, Weissman BN, Palestro CJ, Fox MG, Bell AM, Blankenbaker DG, et al. ACR Appropriateness criteria(R) imaging after total hip arthroplasty. J Am Coll Radiol. 2023;20(11S):S413–32.
62.
Kurtz SM, Lau EC, Son MS, Chang ET, Zimmerli W, Parvizi J. Are we winning or losing the battle with periprosthetic joint infection: trends in periprosthetic joint infection and mortality risk for the Medicare population. J Arthroplasty. 2018;33(10):3238–45.PubMedCrossRef
63.
Yue B, Tang T. The use of nuclear imaging for the diagnosis of periprosthetic infection after knee and hip arthroplasties. Nucl Med Commun. 2015;36(4):305–11.PubMedCrossRef
64.
Kiran M, Donnelly TD, Armstrong C, Kapoor B, Kumar G, Peter V. Diagnostic utility of fluorodeoxyglucose positron emission tomography in prosthetic joint infection based on MSIS criteria. Bone Joint J. 2019;101–B(8):910–4.PubMedCrossRef
65.
Wang Y, Wang R, Geng L, Li Q, Qi E, Shi Y, et al. Different uptake patterns of (68)Ga-FAPI in aseptic loosening and periprosthetic joint infection of hip arthroplasty: a case series and literature review. Front Med (Lausanne). 2022;9:1014463.PubMedCrossRef
66.
Anil U, Singh V, Schwarzkopf R. Diagnosis and detection of subtle aseptic loosening in total hip arthroplasty. J Arthroplasty. 2022;37(8):1494–500.PubMedCrossRef
67.
Mayer-Wagner S, Mayer W, Maegerlein S, Linke R, Jansson V, Muller PE. Use of 18F-FDG-PET in the diagnosis of endoprosthetic loosening of knee and hip implants. Arch Orthop Trauma Surg. 2010;130(10):1231–8.PubMedCrossRef
68.
Koob S, Gaertner FC, Jansen TR, Schmolders J, Gravius S, Strunk H, et al. Diagnosis of peri-prosthetic loosening of total hip and knee arthroplasty using (18)F-fluoride PET/CT. Oncotarget. 2019;10(22):2203–11.PubMedPubMedCentralCrossRef
69.
Xu T, Zeng Y, Yang X, Liu G, Lv T, Yang H, et al. Application of (68)Ga-citrate PET/CT for differentiating periprosthetic joint infection from aseptic loosening after joint replacement surgery. Bone Joint Res. 2022;11(6):398–408.PubMedPubMedCentralCrossRef
70.
Kimura M, Kaku N, Kubota Y, Tagomori H, Tsumura H. Fluorodeoxyglucose positron-emission tomography/computed tomography and magnetic resonance imaging for adverse local tissue reactions near metal implants after total hip arthroplasty: a preliminary report. Clin Orthop Surg. 2021;13(3):320–8.PubMedPubMedCentralCrossRef
71.
72.
Broberg JS, Koff MF, Howard JL, Lanting BA, Potter HG, Teeter MG. A multimodal assessment of cementless tibial baseplate fixation using radiography, radiostereometric analysis, and magnetic resonance imaging. J Orthop Res. 2023;42(1):100–8.PubMedCrossRef
73.
Cuccurullo V, Manti F, De Risi M, Cascini GL. FDG-CT/PET false positive case in hip prosthesis: a clue to avoid error. Radiol Case Rep. 2021;16(9):2601–4.PubMedPubMedCentralCrossRef
74.
Mendoza H, Nosov A, Pandit-Taskar N. Molecular imaging of sarcomas with FDG PET. Skeletal Radiol. 2023;52(3):461–75.PubMedCrossRef
75.
76.
Behzadi AH, Raza SI, Carrino JA, Kosmas C, Gholamrezanezhad A, Basques K, et al. Applications of PET/CT and PET/MR imaging in primary bone malignancies. PET Clin. 2018;13(4):623–34.PubMedPubMedCentralCrossRef
77.
Expert Panel on Musculoskeletal I, Pierce JL, Perry MT, Wessell DE, Lenchik L, Ahlawat S, et al. ACR appropriateness criteria(R) suspected osteomyelitis, septic arthritis, or soft tissue infection (excluding spine and diabetic foot): 2022 update. J Am Coll Radiol. 2022;19(11S):S473–87.
78.
Signore A, Casali M, Lauri C. An easy and practical guide for imaging infection/inflammation by [(18)F]FDG PET/CT. Clin Transl Imaging. 2021;9(4):283–97.PubMedPubMedCentralCrossRef
79.
Yoon D, Kogan F, Gold GE, Biswal S. Identifying musculoskeletal pain generators using clinical PET. Semin Musculoskelet Radiol. 2020;24(4):441–50.PubMedCrossRef
80.
Oo WM, Little C, Duong V, Hunter DJ. The development of disease-modifying therapies for osteoarthritis (DMOADs): the evidence to date. Drug Des Devel Ther. 2021;15:2921–45.PubMedPubMedCentralCrossRef
81.
Barrio JR, Huang SC, Phelps ME. In vivo assessment of neurotransmitter biochemistry in humans. Annu Rev Pharmacol Toxicol. 1988;28:213–30.PubMedCrossRef
82.
83.
Administration of Radioactive Substances Advisory Committee. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2023. https://​www.​gov.​uk/​arsac. Accessed 3 Jan 2024.
84.
Mingels C, Caobelli F, Alavi A, Sachpekidis C, Wang M, Nalbant H, et al. Total-body PET/CT or LAFOV PET/CT? Axial field-of-view clinical classification. Eur J Nucl Med Mol Imaging. 2023;51(4):951–3.PubMedCrossRef
85.
Cherry SR, Jones T, Karp JS, Qi J, Moses WW, Badawi RD. Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care. J Nucl Med : Off Publ Soc Nucl Med. 2018;59(1):3–12.CrossRef
86.
Carson RE. Tracer kinetic modeling in PET. In: Valk PE, Bailey DL, Townsend DW, Maisey MN, editors. Positron emission tomography: Basic science and clinical practice. Springer-Verlag London Ltd; 2003. pp. 147–179.
87.
Volpi T, Maccioni L, Colpo M, Debiasi G, Capotosti A, Ciceri T, et al. An update on the use of image-derived input functions for human PET studies: new hopes or old illusions? EJNMMI Res. 2023;13(1):97.PubMedPubMedCentralCrossRef
88.
Carson RE, Naganawa M, Gallezot J-D. PET quantification and kinetic analysis. Molecular Imaging of Neurodegenerative Disorders: Springer; 2023. p. 183–94.
89.
Badawi RD, Shi H, Hu P, Chen S, Xu T, Price PM, et al. First human imaging studies with the EXPLORER total-body PET scanner. J Nucl Med : Off Publ Soc Nucl Med. 2019;60(3):299–303.CrossRef
90.
Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020;117(5):2265–7.PubMedPubMedCentralCrossRef
91.
Pantel AR, Viswanath V, Daube-Witherspoon ME, Dubroff JG, Muehllehner G, Parma MJ, et al. PennPET Explorer: human imaging on a whole-body imager. J Nucl Med. 2020;61(1):144–51.PubMedPubMedCentralCrossRef
92.
Ng QK, Triumbari EKA, Omidvari N, Cherry SR, Badawi RD, Nardo L. Total-body PET/CT - first clinical experiences and future perspectives. Semin Nucl Med. 2022;52(3):330–9.PubMedPubMedCentralCrossRef
93.
Alberts I, Hünermund J-N, Prenosil G, Mingels C, Bohn KP, Viscione M, et al. Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT. Eur J Nucl Med Mol Imaging. 2021;48:2395–404.PubMedPubMedCentralCrossRef
94.
Chaudhari AJ, Raynor WY, Gholamrezanezhad A, Werner TJ, Rajapakse CS, Alavi A. Total-body PET imaging of musculoskeletal disorders. PET clinics. 2021;16(1):99–117.PubMedPubMedCentralCrossRef
95.
Abdelhafez Y, Raychaudhuri SP, Mazza D, Sarkar S, Hunt HL, McBride K, et al. Total-body 18 F-FDG PET/CT in autoimmune inflammatory arthritis at ultra-low dose: initial observations. J Nucl Med. 2022;63(10):1579–85.PubMedPubMedCentralCrossRef
96.
Chaudhari AJ, Abdelhafez YG, Nardo L, Raychaudhuri SP. EXPLORing arthritis with total-body positron emission tomography. Semin Musculoskelet Radiol. 2023;27(06):632–40.PubMedCrossRef
Metadata
Title
Multimodal positron emission tomography (PET) imaging in non-oncologic musculoskeletal radiology
Authors
Feliks Kogan
Daehyun Yoon
Matthew G. Teeter
Abhijit J. Chaudhari
Laurel Hales
Marco Barbieri
Garry E. Gold
Yael Vainberg
Ananya Goyal
Lauren Watkins
Publication date
16-03-2024
Publisher
Springer Berlin Heidelberg
Published in
Skeletal Radiology
Print ISSN: 0364-2348
Electronic ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-024-04640-4